Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the development of cell culture technologies and techniques for therapeutic applications. Its commercial products include good tissue practice laboratory infrastructure, adipose-derived stem cells (ADSC) for regenerative medicine, and CIK and DC-CIK against cancers. The company also develops medicines for various types of cancers, cell immunotherapy, and stem cell regenerative therapy technologies. In addition, it engages in the research and development of chimeric antigen receptor T cell (CAR-T), CAR-NK and CAR-?dT, and gene-modified ADSC. Further, the company develops products for B-NHL, ovarian cancer, multiple myeloma, and thyroid cancer indications. The company was founded in 2017 and is based in Taipei, Taiwan.